Home › Research › Tau biomarkers
The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk
Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL et al.. Science translational medicine, 2018-06-20
Topic: Brain proteins, microglia and lab models
Plain-language summary
Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) levels in the cerebrospinal fluid (CSF) have been associated with Alzheimer disease (AD) status. TREM2 plays a critical role in microglial activation, survival, and phagocytosis; however, the pathophysiological role of sTREM2 in AD is not well understood. Understanding the role of sTREM2 in AD may help reveal biological mechanisms underlying AD and identify novel therapeutic targets.
What this study adds
Evidence grade: Low
This genome-wide association study found that common variants in the MS4A gene region were associated with cerebrospinal fluid soluble TREM2 levels, linking this gene cluster to Alzheimer's disease risk. It identifies a possible biological mechanism and target but does not report any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Deming, Y., Filipello, F., Cignarella, F., Cantoni, C., Hsu, S., Mikesell, R., et al. (2018). The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk. Science translational medicine. https://doi.org/10.1101/352179
Vancouver
Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, et al. The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk. Science translational medicine. 2018. doi:10.1101/352179.
BibTeX
@article{deming2018-3f7a9435,
author = {Deming, Y. and Filipello, F. and Cignarella, F. and Cantoni, C. and Hsu, S. and Mikesell, R. and Li, Z. and Del-Aguila, J. L. and others},
title = {{The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk}},
journal = {Science translational medicine},
year = {2018},
doi = {10.1101/352179},
url = {https://doi.org/10.1101/352179}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- TREM2 plays a critical role in microglial activation, survival, and phagocytosis; however, the pathophysiological role of sTREM2 in AD is not well understood.
- Understanding the role of sTREM2 in AD may help reveal biological mechanisms underlying AD and identify novel therapeutic targets.
- We performed a genome-wide association study (GWAS) to identify genetic modifiers of CSF sTREM2 levels.
- Common variants in the membrane-spanning 4-domains subfamily A ( MS4A ) gene region were associated with higher CSF sTREM2 levels (rs1582763; P = 1.15×10 −15 ) and replicated in independent datasets.
Why it matters
This genome-wide association study found that common variants in the MS4A gene region were associated with cerebrospinal fluid soluble TREM2 levels, linking this gene cluster to Alzheimer's disease risk. It identifies a possible biological mechanism and target but does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 64 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Science translational medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31413141) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 23 of the 64 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.